An open-label, multicenter extension study of pertuzumab (rhuMAb 2C4) in subjects treated with pertuzumab in a previous Genentech-sponsored phase II cancer study

Trial Profile

An open-label, multicenter extension study of pertuzumab (rhuMAb 2C4) in subjects treated with pertuzumab in a previous Genentech-sponsored phase II cancer study

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2015

At a glance

  • Drugs Pertuzumab (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 01 Jan 2008 Status change from in progress to completed.
    • 02 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top